E-cadherin expression in tumor emboli in gastric cancer

Close metadata

OBJECTIVE

To determine the level of E-cadherin expression in tumor emboli, to compare it with expression in a tumor, to determine the dependence of E-cadherin expression in tumor emboli on the clinical and morphological characteristics of gastric cancer.

MATERIAL AND METHODS

We used samples of surgical material from 280 patients with a verified diagnosis of gastric cancer. E-cadherin expression was determined by immunohistochemical method. The results of the reactions were assessed semi-quantitatively and compared with the main clinical and morphological characteristics of gastric cancer (histological type according to the WHO classification 2019, histological type according to the classification of P. Lauren, clinical stage, depth of invasion (T), number of metastases in lymph nodes (N), presence or/absence of distant metastases (M), tumor localization in the stomach).

RESULTS

Among 280 cases of cancer, emboli were detected only in 67 cases, used for further analysis. The rest of the samples were excluded from the analysis, since emboli did not get into the sections during the cutting of immunohistochemical preparations. The expression of E-cadherin in tumor emboli was significantly higher (p<0.001) than in tumor tissue. At the same time, no cases identified where the level of E-cadherin decreased in emboli compared to the tumor. A significant increase in the expression of E-cadherin in tumor emboli compared to the primary tumor was noted for all histological types according to WHO 2019, for intermediate and diffuse types according to the P. Lauren classification (p<0.001). Comparison of expression in emboli and tumors for neoplasms with different depths of invasion (T), different stages and different localizations did not reveal statistically significant differences. An increase in the expression of E-cadherin in emboli compared to tumors was characterized by a higher level of significance in the presence of metastases (N1, N2, N3a, N3b; p<0.001) than in the absence of metastases (N0; p=0.016).

CONCLUSION

The study revealed a statistically significant increase in the expression of E-cadherin in tumor emboli compared to the primary tumor, which is evidence of its important role in maintaining the integrity of emboli and tumor dissemination.

Keywords:

E-cadherin

gastric cancer

emboli

expression

immunohistochemistry

Authors:

Danilova N.V.

Lomonosov Moscow State University

SPIN RSCI: 6878-2025
Scopus AuthorID: 36613033400
ResearcherID: H-6477-2014
ORCID: 0000-0001-7848-6707

Mikhailov I.A.

Center for Expertise and Quality Control of Medical Care;
Lomonosov Moscow State University

SPIN RSCI: 5798-0749
Scopus AuthorID: 57203900904
ResearcherID: I-9035-2017
ORCID: 0000-0001-8020-369X

Oleynikova N.A.

Lomonosov Moscow State University

SPIN RSCI: 4076-2637
Scopus AuthorID: 57193513523
ResearcherID: H-7672-2014
ORCID: 0000-0001-8564-8874

Polushkina T.V.

Lomonosov Moscow State University

ORCID: 0000-0001-5074-3513

Received:

26.02.2021

Accepted:

05.03.2021

List of references:

Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, Caldeira J, Costa AM, Simões-Correia J, Oliveira MJ, Pinheiro H, Pinho SS, Mateus R, Reis CA, Leite M, Fernandes MS, Schmitt F, Carneiro F, Figueiredo C, Oliveira C, Seruca R. Epithelial E- P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta. 2012;1826(2):297-311. https://doi.org/10.1016/j.bbcan.2012.05.002
Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol. 2005;6(8):622-634. https://doi.org/10.1038/nrm1699
Halbleib,J.M, Nelson WJ. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 2006;20(23): 3199-3214. https://doi.org/10.1101/gad.1486806
Lien WH, Klezovitch O, Vasioukhin V. Cadherin-catenin proteins in vertebrate development. Curr Opin Cell Biol. 2006;18(5):499-506. https://doi.org/10.1016/j.ceb.2006.07.001
Hulpiau P, van Roy F. Molecular evolution of the cadherin superfamily. Int J Biochem Cell Biol. 2009;41(2):349-369. https://doi.org/10.1016/j.biocel.2008.09.027
Redies C, Vanhalst K, Roy F. δ-Protocadherins: unique structures and functions. Cell Mol Life Sci. 2005;62(23):2840-2852. https://doi.org/10.1007/s00018-005-5320-z
van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65(23):3756-3788. https://doi.org/10.1007/s00018-008-8281-1
Blaschuk OW, Sullivan R, David S, Pouliot Y. Identification of a cadherin cell adhesion recognition sequence. Dev Biol. 1990; 139(1):227-229. https://doi.org/10.1016/0012-1606(90)90290-y
Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta. 2008;1778(3):660-669. https://doi.org/10.1016/j.bbamem.2007.07.012
Kobielak A, Fuchs E. Alpha-catenin: at the junction of intercellular adhesion and actin dynamics. Nat Rev Mol Cell Biol. 2004;5(8): 614-625. https://doi.org/10.1038/nrm1433
Perez-Moreno M, Fuchs E. Catenins: keeping cells from getting their signals crossed. Dev Cell. 2006;11(5):601-612. https://doi.org/10.1016/j.devcel.2006.10.010
Reynolds AB, Roczniak-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene. 2004;23(48):7947-7956. https://doi.org/10.1038/sj.onc.1208161
Scott JA, Yap AS. Cinderella no longer: alpha-catenin steps out of cadherin’s shadow. J Cell Sci. 2006;119(Pt22):4599-4605. https://doi.org/10.1242/jcs.03267
Gumbiner BM, McCrea PD. Catenins as mediators of the cytoplasmic functions of cadherins. J Cell Sci Suppl. 1993;17(Suppl):155-158. https://doi.org/10.1242/jcs.1993.supplement_17.22
Makrilia N, Kollias A, Manolopoulos L, Syrigos K. Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 2009;27(10):1023-1037. https://doi.org/10.3109/07357900902769749
Mareel M, Oliveira MJ, Madani I. Cancer invasion and metastasis: interacting ecosystems. Virchows Arch. 2009;454(6):599-622. https://doi.org/10.1007/s00428-009-0784-0
Van Aken E, De Wever O, Correia da Rocha AS, Mareel M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch. 2001;439(6):725-751. https://doi.org/10.1007/s004280100516
Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol. 2009;1(6):a003129. https://doi.org/10.1101/cshperspect.a003129
Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4(2):118-132. https://doi.org/10.1038/nrc1276
Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004;1014:155-163. https://doi.org/10.1196/annals.1294.016
Strumane K, Berx G, Van Roy F. Cadherins in cancer. Handb Exp Pharmacol. 2004(165):69-103. https://doi.org/10.1007/978-3-540-68170-0_4
Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol. 1989;108(6):2435-2447.
Mareel MM, Behrens J, Birchmeier W, De Bruyne GK, Vleminckx K, Hoogewijs A, Fiers WC, Van Roy FM. Down-regulation of E-cadherin expression in Madin Darby canine kidney (MDCK) cells inside tumors of nude mice. Int J Cancer. 1991;47(6):922-928. https://doi.org/10.1002/ijc.2910470623
Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998;392(6672):190-193. https://doi.org/10.1038/32433
Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66(1):107-119. https://doi.org/10.1016/0092-8674(91)90143-m
Luo J, Sharma N, Seftor EA, De Larco J, Heidger PM, Hendrix MJ, Lubaroff DM. Heterogeneous expression of invasive and metastatic properties in a prostate tumor model. Pathol Oncol Res. 1997;3(4):264-271. https://doi.org/10.1007/bf02904285
Osada T, Sakamoto M, Ino Y, Iwamatsu A, Matsun Y, Muto T, Hirohashi S. E-cadherin is involved in the intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 1996;24(6):1460-1467. https://doi.org/10.1053/jhep.1996.v24.pm0008938181
Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell. 1998;94(3):353-362. https://doi.org/10.1016/s0092-8674(00)81478-6
Van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res. 2011;728(1-2): 23-34. https://doi.org/10.1016/j.mrrev.2011.05.002
Alpaugh ML, Tomlinson JS, Kasraeian S, Barsky SH. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene. 2002;21(22):3631-3643. https://doi.org/10.1038/sj.onc.1205389
Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH. A novel human xenograft model of inflammatory breast cancer. Cancer Res. 1999;59(20):5079-5084.
Kleer CG, van Golen KL, Braun T, Merajver SD. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol. 2001;14(5):458-464. https://doi.org/10.1038/modpathol.3880334
Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001;61(13):5231-5241.
Ye Y, Tellez JD, Durazo M, Belcher M, Yearsley K, Barsky SH. E-cadherin accumulation within the lymphovascular embolus of inflammatory breast cancer is due to altered trafficking. Anticancer Res. 2010;30(10):3903-3910.
Kang HG, Jenabi JM, Zhang J, Keshelav N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007;67(7):3094-3105. https://doi.org/10.1158/0008-5472.can-06-3259
Kantak SS, Kramer RH. E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem. 1998;273(27):16953-16961. https://doi.org/10.1074/jbc.273.27.16953
Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994;54(14):3845-3852.
Becker KF, Kremmer E, Eulitz M, Becker I, Handschuh G, Schuhmacher C, Müller W, Gabbert HE, Ochiai A, Hirohashi S, Höfler H. Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody. Am J Pathol. 1999;155(6):1803-1809. https://doi.org/10.1016/s0002-9440(10)65497-1
Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, Diosdado B, Grabsch H, Santos MA, Meijer G, Seruca R, Carvalho B, Oliveira C. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol. 2012;228(1):31-44. https://doi.org/10.1002/path.4032
Machado JC, Oliveira C, Carvalho R, Soares P, Berx G, Caldas C, Seruca R, Carneiro F, Sobrinho-Simoes M. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 2001;20(12):1525-1528. https://doi.org/10.1038/sj.onc.1204234
Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, Deshpande V, Mino-Kenudson M, Srivastava A, Lennerz JK, Hong TS, Kwak EL, Lauwers GY. A protein and mRNA expression-based classification of gastric cancer. Mod Pathol. 2016;29(7):772-784. https://doi.org/10.1038/modpathol.2016.55
Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ. E-cadherin’s dark side: possible role in tumor progression. Biochim Biophys Acta. 2012;1826(1):23-31. https://doi.org/10.1016/j.bbcan.2012.03.002

Close metadata